Statin use in prediabetic patients: rationale and results to date

Therapeutic Advances in Chronic Disease
Anastazia KeiMoses Elisaf

Abstract

Prediabetes increases the risk for new-onset diabetes mellitus in patients receiving statins and this risk is dose- and time- dependent. Explanations for the conversion of a predisposed individual to diabetes are ambiguous including reductions in ubiquinone and adiponectin levels. However, the risk of new-onset diabetes mellitus is far outweighed by the statin-induced considerable decrease in cardiovascular events. Thus, prediabetic patients at high cardiovascular risk should not be denied high-dose statin therapy due to the small increase in the risk of developing diabetes since statins, especially at higher doses, cause greater reductions in cardiovascular events compared with standard statin doses. Moreover, lifestyle modification or even antidiabetic drugs are highly recommended in these individuals.

References

Feb 8, 2002·The New England Journal of Medicine·William C KnowlerUNKNOWN Diabetes Prevention Program Research Group
Jan 22, 2005·Fundamental & Clinical Pharmacology·Michael Schachter
Jun 9, 2005·Journal of Atherosclerosis and Thrombosis·Hiroshi MabuchiJunji Kobayashi
Nov 17, 2009·Diabetes Research and Clinical Practice·William L BakerCraig I Coleman
May 29, 2010·Current Vascular Pharmacology·Michael S KostapanosMoses S Elisaf
Apr 2, 2011·Journal of the American College of Cardiology·David D WatersPhilip Barter
Jun 23, 2011·JAMA : the Journal of the American Medical Association·David PreissKausik K Ray
Jan 25, 2012·Toxicology and Applied Pharmacology·P SirventJ Mercier
Apr 27, 2012·The New England Journal of Medicine·Allison B Goldfine
Jun 12, 2012·Lancet·Adam G TabákMika Kivimäki
Dec 12, 2012·Journal of the American College of Cardiology·David D WatersTerje R Pedersen
Jan 29, 2013·The American Journal of Cardiology·Eliano Pio NavareseJacek Kubica
Mar 19, 2013·Metabolic Syndrome and Related Disorders·Shobana Ganesan, Matthew K Ito
Jul 6, 2013·Expert Opinion on Pharmacotherapy·Yi ZhouShao-Hua Wang
Dec 21, 2013·Diabetes Care·UNKNOWN American Diabetes Association
Dec 24, 2013·The American Journal of Cardiology·Kang-Ling WangChern-En Chiang
Jan 1, 2014·World Journal of Diabetes·Anastazia KeiMoses Elisaf
May 6, 2014·Journal of Clinical Lipidology·Kevin C Maki The Diabetes Subpanel of the National Lipid Association Expert Panel
Aug 20, 2014·Current Vascular Pharmacology·Vasilios G AthyrosDimitri P Mikhailidis
Sep 12, 2014·Journal of Pharmacology & Pharmacotherapeutics·Umme AimanRahat Ali Khan
Sep 14, 2014·The Lancet. Diabetes & Endocrinology·Sune F Nielsen, Børge G Nordestgaard
Nov 16, 2014·Current Atherosclerosis Reports·Dick C ChanGerald F Watts
Dec 3, 2014·BMJ Open Diabetes Research & Care·Dominika NowisJakub Golab
Dec 9, 2014·Metabolism: Clinical and Experimental·Niki KatsikiChristos S Mantzoros
Dec 20, 2014·Journal of Clinical Lipidology·Harold E BaysTerry A Jacobson
Jan 13, 2015·Atherosclerosis. Supplements·Lorenzo Arnaboldi, Alberto Corsini

❮ Previous
Next ❯

Citations

Aug 9, 2016·Atherosclerosis·Piotr ChruścielUNKNOWN Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group
Feb 8, 2018·Journal of Cardiovascular Pharmacology and Therapeutics·Theodosios D FilippatosMoses S Elisaf
May 28, 2019·Diabetes/metabolism Research and Reviews·Victoria A ZigmontSusan E Olivo-Marston
Apr 9, 2018·Emergency Medicine Journal : EMJ·Morgan C BroccoliEmilie J Calvello Hynes
Jul 12, 2019·Emergency Medicine Journal : EMJ·Chancy ChavulaLee A Wallis

❮ Previous
Next ❯

Software Mentioned

JUPITER
FINDRISK

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.